Literature DB >> 19145056

Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.

Kimihito C Kawabata1, Shotaro Hagiwara, Ayako Takenouchi, Akira Tanimura, Junko Tanuma, Natsuo Tachikawa, Akiyoshi Miwa, Shinichi Oka.   

Abstract

AIDS-related lymphoma (ARL) is a serious complication of HIV infection. We performed MEAM (MCNU + etoposide + cytarabine + L-PAM) regimen with autologous stem cell transplantation (ASCT) for three patients with refractory or relapsed ARL. All three patients had been treated with highly active anti-retroviral therapy (HAART) during the course of the treatment regimen and ASCT. The regimen was well tolerable, and no uncontrollable infection was noted. All patients are still alive and maintain complete remission at 24, 20 and 9 months after transplantation. ASCT using MEAM regimen as a conditioning regimen was feasible for our patients with refractory or relapsed ARL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19145056     DOI: 10.2169/internalmedicine.48.1295

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.

Authors:  Shojiro Inano; Makoto Iwasaki; Yoshihiro Iwamoto; Yuki Sueki; Akiko Fukunaga; Soshi Yanagita; Nobuyoshi Arima
Journal:  Int J Hematol       Date:  2013-12-14       Impact factor: 2.490

2.  Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation.

Authors:  Hideki Tsujimura; Toshiko Miyaki; Shuhei Yamada; Takeaki Sugawara; Mikiko Ise; Shintaro Iwata; Tsukasa Yonemoto; Dai Ikebe; Makiko Itami; Kyoya Kumagai
Journal:  Int J Hematol       Date:  2014-07-26       Impact factor: 2.490

3.  Upfront high-dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high-risk diffuse large B-cell lymphoma.

Authors:  Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

4.  Autologous peripheral blood stem cell transplantation for relapsed/refractory HIV-associated lymphoma: a phase II clinical study.

Authors:  Shotaro Hagiwara; Hirokazu Nagai; Tomoko Uehira; Akiko M Saito; Seiji Okada
Journal:  Int J Hematol       Date:  2019-12-13       Impact factor: 2.490

5.  Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention.

Authors:  Naoto Okada; Takeshi Hanafusa; Shinji Abe; Chiemi Sato; Toshimi Nakamura; Kazuhiko Teraoka; Masahiro Abe; Kazuyoshi Kawazoe; Keisuke Ishizawa
Journal:  Support Care Cancer       Date:  2016-04-29       Impact factor: 3.603

6.  Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy.

Authors:  Hiroki Goto; Shotaro Hagiwara; Risen Hirai; Takahiko Miyama; Haruhito Honda; Amane Tagashira; Toshihiko Iizuka; Makoto Mochizuki; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka; Akiyoshi Miwa
Journal:  Rare Tumors       Date:  2011-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.